U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

HER2-Negative Breast Carcinoma

MedGen UID:
1714400
•Concept ID:
C5238910
•
Neoplastic Process
Synonyms: HER2 Negative Breast Adenocarcinoma; HER2 Negative Breast Carcinoma

Definition

A breast adenocarcinoma that is negative for the expression of the HER2 receptor. [from NCI]

Professional guidelines

PubMed

Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer.
Schlam I, Giordano A, Tolaney SM
Expert Opin Drug Saf 2023 Jul-Dec;22(12):1149-1156. Epub 2023 Dec 18 doi: 10.1080/14740338.2023.2288147. PMID: 37994878
An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L, Rugo HS, Jackisch C
Target Oncol 2021 May;16(3):255-282. Epub 2021 Mar 12 doi: 10.1007/s11523-021-00796-4. PMID: 33710534Free PMC Article
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL
J Clin Oncol 2021 May 1;39(13):1485-1505. Epub 2021 Jan 28 doi: 10.1200/JCO.20.03399. PMID: 33507815Free PMC Article

Recent clinical studies

Etiology

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F
Br J Cancer 2015 Sep 29;113(7):996-1002. Epub 2015 Sep 17 doi: 10.1038/bjc.2015.239. PMID: 26379080Free PMC Article
Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B
J BUON 2015 Jan-Feb;20(1):28-34. PMID: 25778292
Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.
Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F
Br J Cancer 2014 Apr 29;110(9):2195-200. Epub 2014 Apr 8 doi: 10.1038/bjc.2014.143. PMID: 24714751Free PMC Article
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M
J Cancer Res Clin Oncol 2013 Sep;139(9):1563-8. Epub 2013 Jul 28 doi: 10.1007/s00432-013-1479-0. PMID: 23892410
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X
PLoS One 2012;7(4):e35184. Epub 2012 Apr 18 doi: 10.1371/journal.pone.0035184. PMID: 22529987Free PMC Article

Diagnosis

Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E
Cancer 2017 Jan 1;123(1):131-137. Epub 2016 Aug 15 doi: 10.1002/cncr.30271. PMID: 27526056Free PMC Article
Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B
J BUON 2015 Jan-Feb;20(1):28-34. PMID: 25778292
Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.
Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F
Br J Cancer 2014 Apr 29;110(9):2195-200. Epub 2014 Apr 8 doi: 10.1038/bjc.2014.143. PMID: 24714751Free PMC Article
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M
J Cancer Res Clin Oncol 2013 Sep;139(9):1563-8. Epub 2013 Jul 28 doi: 10.1007/s00432-013-1479-0. PMID: 23892410
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A
Cancer 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. PMID: 18098228

Therapy

Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas.
Gologorsky R, Cureton E, Shim V
Perm J 2019;23:18-088. doi: 10.7812/TPP/18-088. PMID: 30624197Free PMC Article
Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E
Cancer 2017 Jan 1;123(1):131-137. Epub 2016 Aug 15 doi: 10.1002/cncr.30271. PMID: 27526056Free PMC Article
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E, Malin D, Good DM, Cryns VL
Clin Cancer Res 2015 Jun 15;21(12):2780-91. Epub 2015 Feb 27 doi: 10.1158/1078-0432.CCR-14-2792. PMID: 25724522Free PMC Article
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M
J Cancer Res Clin Oncol 2013 Sep;139(9):1563-8. Epub 2013 Jul 28 doi: 10.1007/s00432-013-1479-0. PMID: 23892410
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A
Cancer 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. PMID: 18098228

Prognosis

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
Rossi L, Laas E, Mallon P, Vincent-Salomon A, Guinebretiere JM, Lerebours F, Rouzier R, Pierga JY, Reyal F
Br J Cancer 2015 Sep 29;113(7):996-1002. Epub 2015 Sep 17 doi: 10.1038/bjc.2015.239. PMID: 26379080Free PMC Article
Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B
J BUON 2015 Jan-Feb;20(1):28-34. PMID: 25778292
Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.
Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F
Br J Cancer 2014 Apr 29;110(9):2195-200. Epub 2014 Apr 8 doi: 10.1038/bjc.2014.143. PMID: 24714751Free PMC Article
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E, Bogina G, Bria E, Vergine M, Zamboni G, Pedron S, Daniele I, Furlanetto J, Carbognin L, Marconi M, Manfrin E, Ibrahim M, Miller K, Tortora G, Molino A, Jasani B, Beccari S, Bonetti F, Chilosi M, Martignoni G, Brunelli M
J Cancer Res Clin Oncol 2013 Sep;139(9):1563-8. Epub 2013 Jul 28 doi: 10.1007/s00432-013-1479-0. PMID: 23892410
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, Peyro-Saint-Paul H, Pierga JY, Cottu P, Dieras V, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X
PLoS One 2012;7(4):e35184. Epub 2012 Apr 18 doi: 10.1371/journal.pone.0035184. PMID: 22529987Free PMC Article

Clinical prediction guides

Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY, Krystel-Whittemore M, Patil S, Pareja F, Bowser ZL, Dickler MN, Norton L, Morrow M, Hudis CA, Brogi E
Cancer 2017 Jan 1;123(1):131-137. Epub 2016 Aug 15 doi: 10.1002/cncr.30271. PMID: 27526056Free PMC Article
Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.
Laas E, Mallon P, Duhoux FP, Hamidouche A, Rouzier R, Reyal F
PLoS One 2016;11(2):e0148957. Epub 2016 Feb 19 doi: 10.1371/journal.pone.0148957. PMID: 26895349Free PMC Article
Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O, Yalcintas Arslan U, Durnali A, Uyetrk U, Demirci A, Tastekin D, Ekinci A, Esbah O, Turker I, Uysal Sonmez O, Oksuzoglu B
J BUON 2015 Jan-Feb;20(1):28-34. PMID: 25778292
Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma.
Daveau C, Baulies S, Lalloum M, Bollet M, Sigal-Zafrani B, Sastre X, Vincent-Salomon A, Tardivon A, Thibault F, Pierga JY, Cottu P, Sablin MP, Rouzier R, Malhaire C, Mallon P, Reyal F
Br J Cancer 2014 Apr 29;110(9):2195-200. Epub 2014 Apr 8 doi: 10.1038/bjc.2014.143. PMID: 24714751Free PMC Article
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A
Cancer 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226. PMID: 18098228

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...